Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Go back to Gilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment| Gilead Sciences (NASDAQ: GILD) | Delayed: 127.88 +4.04 (3.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.84 | 52 Week High | $108.63 | |||
| Open | $125.25 | 52 Week Low | $71.39 | |||
| Day High | $128.70 | P/E | 70.65 | |||
| Day Low | $125.00 | EPS | $1.81 | |||
| Volume | 19,908,480 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 128.66 +3.21 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.45 | 52 Week High | $65.46 | |||
| Open | $125.83 | 52 Week Low | $47.97 | |||
| Day High | $128.78 | P/E | 87.52 | |||
| Day Low | $125.83 | EPS | $1.47 | |||
| Volume | 18,891,511 | |||||
